Resveratrol potentiates the effect of bortezomib and thalidomide on NF-κB and STAT3 activation in MM cells. (A) U266 cells (1 × 106/mL) were treated with 25 μM resveratrol or 10 nM bortezomib alone or in combination for 24 hours at 37°C and then tested for NF-κB by EMSA. (B) U266 cells (1 × 106/mL) were treated with 25 μM resveratrol or 10 μg/mL thalidomide alone or in combination for 24 hours at 37°C and then tested for NF-κB by EMSA. The results shown are representative of 3 independent experiments. (C) U266 cells (1 × 106/mL) were treated with 25 μM resveratrol or 10 nM bortezomib alone or in combination for 3 hours at 37°C. Whole-cell extracts were prepared, and 30-μg portions of those extracts were resolved on 7.5% SDS-PAGE gel, electrotransferred onto nitrocellulose membranes, and probed for antibody against phospho-STAT3. The same blots were stripped and reprobed with STAT3 antibody to verify equal protein loading. (D) U266 cells (1 × 106/mL) were treated with 25 μM resveratrol or 10 μg/mL thalidomide alone or in combination for 3 hours at 37°C after which Western blotting was performed as described for panel C. The results shown are representative of 3 independent experiments.
